Last reviewed · How we verify
Carrellizumab + Capecitabine
Carrellizumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with capecitabine, a fluoropyrimidine chemotherapy agent.
Carrellizumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with capecitabine, a fluoropyrimidine chemotherapy agent. Used for Gastric or gastroesophageal junction cancer (Phase 3 development).
At a glance
| Generic name | Carrellizumab + Capecitabine |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | PD-L1 inhibitor + fluoropyrimidine chemotherapy |
| Target | PD-L1 (carrellizumab); thymidylate synthase (capecitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carrellizumab enhances T-cell mediated anti-tumor immunity by preventing PD-L1-mediated immune checkpoint suppression. Capecitabine is a prodrug that converts to 5-fluorouracil in tumor tissue, inhibiting thymidylate synthase and disrupting DNA synthesis. The combination leverages immunotherapy with conventional chemotherapy for enhanced efficacy.
Approved indications
- Gastric or gastroesophageal junction cancer (Phase 3 development)
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Nausea
- Immune-related adverse events (fatigue, rash)
- Myelosuppression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: